Wed 29 April 2026

Policy and Advocacy Impact April 2026

AdPha released a position paper on pharmacist prescribing across team-based care settings, calling for access to PBS-subsidised medicines to be prioritised in future reforms. The paper was informed by a national workshop with key pharmacy leaders, and outlines a fit-for-purpose endorsement pathway for pharmacist prescribers across all settings.

The Pharmacy Board of Australia has since commenced its public consultation on a proposal to establish an Endorsement for scheduled medicines for pharmacists. AdPha will be consulting widely with members over the coming weeks to inform our response.

The Executive Summary of the 24‑month Minimum Stockholding Requirements review has been published, with recommendations on data sharing and PBS–TGA data alignment that reflect AdPha’s longstanding advocacy for stronger, integrated data systems to support medicines shortages management. 

AdPha also met with the Generic and Biosimilar Medicines Association (GBMA) and provided input into the development of its white paper on medicines shortages, contributing a hospital pharmacy and end‑user perspective to inform future policy solutions.

Finally, we farewelled Jerry Yik who finished up with AdPha in April. We thank Jerry for his significant contribution to the hospital pharmacy and AdPha’s policy and advocacy work. For any policy or advocacy enquiries, please contact policy@adpha.au.